United States Antimony Corporation (UAMY) presents investors with a complex narrative of opposing forces. The company’s recent quarterly performance fell significantly short of expectations, causing its stock to decline. However, this near-term disappointment is counterbalanced by a substantial new contract that bolsters the long-term outlook.
Major Contract Win Offsets Quarterly Concerns
Just one day before releasing disappointing quarterly figures, UAMY announced a significant five-year agreement with a U.S. industrial company for the supply of antimony trioxide. The contract is valued at up to $106.7 million and includes options for extension that could double its duration.
This new agreement, combined with the previously disclosed $245 million contract from the U.S. Department of Defense, brings UAMY’s total contracted pipeline to over $351 million. CEO Gary C. Evans emphasized that these developments provide “significant long-term revenue growth and stability for our shareholders.”
Third Quarter Performance Falls Short
The company’s third quarter results revealed substantial misses on key financial metrics. Revenue reached only $8.7 million, well below the $12.8 million that market experts had anticipated. More concerning to investors was the earnings per share figure of -$0.04, a sharp contrast to the projected $0.03 profit.
This financial performance triggered a 5.58 percent decline in the stock price, with shares settling at $8.07 following the earnings release.
Should investors sell immediately? Or is it worth buying US Antimony?
Broader Performance Picture Shows Improvement
Despite the quarterly setback, UAMY’s nine-month comparison reveals a more positive trajectory:
* Revenue has surged by 182 percent to $26.23 million
* Gross profit has tripled to $7.22 million
* Gross margins have strengthened from 24 to 28 percent
The apparent contradiction between the strong nine-month performance and weak quarterly results is largely explained by substantial non-cash, stock-based compensation expenses totaling $5.18 million, which negatively impacted the bottom line.
Production Scaling Becomes Critical Focus
The company maintains its commitment to ambitious growth targets. UAMY has reaffirmed its $125 million revenue projection for 2026 without modification. For 2025, the company has provided more specific guidance, narrowing expectations to between $40 and $43 million.
The central challenge now becomes scaling production capacity to meet contractual obligations. Market observers are closely watching whether UAMY can successfully deliver the contracted volumes as scheduled early next year. Successful mining operations at Stibnite Hill, Montana, where high-grade ore is being extracted, provide grounds for optimism about the company’s production capabilities.
UAMY continues its strategic push to establish itself as a fully integrated antimony producer operating independently of Chinese and Russian supply chains. The critical question for investors remains whether these substantial long-term contracts can outweigh the immediate disappointment of missed quarterly expectations, or if the stock will continue facing pressure from underwhelming short-term results.
Ad
US Antimony Stock: Buy or Sell?! New US Antimony Analysis from August 7 delivers the answer:
The latest US Antimony figures speak for themselves: Urgent action needed for US Antimony investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 7.
US Antimony: Buy or sell? Read more here...
